Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

Cipla’s Proventil Generic Gnaws At US Market

Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable’.

Commercial Strategy Sales & Earnings

Zydus Cadila Readies Injectables Push Amid Tepid US Growth Outlook

Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and remdesivir launch looms.

Commercial Sales & Earnings Coronavirus COVID-19

Companies

Set Alert for Companies

Latest From Companies

Antifungal Specialist F2G Gets Near $61m Financing

A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.

Financing Companies

The Top 10 Best-Selling Drugs of 2019

INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market. 

Commercial Companies

Bayer Hopeful Of Sweet Success With KaNDy Buy

Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.

M & A Metabolic Disorders

BetterLife/Altum Merger ‘Triggered By Early COVID-19 Promise’

Created when BetterLife bought Altum at end-July, the merged entity will now focus on advancing the acquired group’s lead asset, an inhaled form of its patented interferon a2b product, as an early treatment for COVID-19.

M & A Companies

Coronavirus Update: Japan Makes Moves On Vaccine Manufacturing

Takeda has linked up with COVID-19 vaccine frontrunner Novavax, while Daiichi Sankyo has been selected by Japan’s Ministry of Health, Labour and Welfare as an official participant under the first round of a national government initiative to build production capacity.

Coronavirus COVID-19 Clinical Trials

Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’

Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.

Clinical Trials Companies
See All

Deals

Set Alert for Deals

Latest From Deals

Cellular Biomedicine To Go Private In Consortium Buyout

Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.

Deals M & A

Finance Watch: 2020 Cell And Gene Therapy Funding Already Bests 2019

Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.

Financing Innovation

Bayer Back In M&A Mode To Boost Pipeline

The head of the German group's pharma BD team tells Scrip that Bayer has created a system which allows it to move quickly when sealing partnerships, as seen with the KaNDy buy on 11 August.

Deals Leadership

Moderna Takes Middle Ground On Pricing With 100 Million Dose US Agreement

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.

Coronavirus COVID-19 Vaccines

Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy

Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.

Deals Business Strategies

Ligand Adds New Expertise, Revenue Potential With Pfenex Buyout

Deal Snapshot: In acquiring its fellow San Diego firm for an estimated deal value of up to $516m, Ligand picks up protein-expression technology, revenue-driving partnerships and the potential for more.

Deals M & A
See All

Strategy

Set Alert for Strategy

Latest From Strategy

Bayer Hopeful Of Sweet Success With KaNDy Buy

Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.

M & A Metabolic Disorders

Bayer Q2 Pharma Sales Ravaged By COVID-19

Turnover at the German group's pharma unit has been hit harder than forecast by the coronavirus pandemic and hefty price cuts linked to China's drug procurement policy but Bayer remains upbeat.

Sales & Earnings Coronavirus COVID-19

Sun Loses Shine In Q1, Testing Times In US

Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.

Commercial Strategy

Novartis India MD On Scalable Digital Solutions, Balancing Work-Life Mix Amid COVID-19

Novartis India chief outlines how the company is navigating the challenging business environment amid the coronavirus pandemic, including for its for-profit social business. Digital solutions are a key part of these efforts and the executive offers advice for those struggling to balance the work-life mix in these testing times.

Commercial Strategy

Early API Momentum At Indian Firms: Not Just A Quarterly Bump?

Alembic and Biocon kick off the Q1 earnings season in India with significant growth in the active pharmaceutical ingredients business and expect to see continued momentum in the area. More Indian firms could gain as customers realign strategies and move away from single sources to de-risk their supply chain, learning from pandemic-related disruptions.

Commercial Coronavirus COVID-19

Novartis Not Tempted To Join COVID-19 Vaccines Race

While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.

Vaccines Coronavirus COVID-19
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Roche Rides Partnership, Digital Wave To Widen China Oncology Drug Access

Amid rising cancer incidence in the Asia Pacific region, Roche tells Scrip in this exclusive interview that it is going "beyond the pill" to widen access to drugs in the increasingly important oncology market.

China Commercial

Vertex Secures Rapid Deal In England For CF Triple Therapy

After a long-standing row with payer NHS England, the rapid market access deal will help Vertex move into growth phase.

Companies Commercial

G1 Believes Boehringer Is Better Bet To Sell Trilaciclib

G1 Therapeutics had been talking about marketing its recently filed myelosuppression therapy for small cell lung cancer on its own. However a deal with Boehringer represents an alternative "capital efficient launch structure."

Cancer Deals
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base

Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.

Cancer Research and Development Strategies

Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus

Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.

Deals Financing

Novartis’s MS Franchise Setback For Ofatumumab In US

Novartis will not start to compete in the increasingly crowded US multiple sclerosis marketplace with ofatumumab this month, as regulators extend the review process for the B-cell depleting therapy until September.

Neurology Approvals
See All
UsernamePublicRestriction

Register